Get the Stockscreener App
366.20
8.15%
27.61
Pre-market:
366.20
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $366.20, with a volume of 5.89M.
It is up +8.15% in the last 24 hours and up +11.77% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$338.59
Open:
$352.03
24h Volume:
5.89M
Relative Volume:
2.04
Market Cap:
$197.19B
Revenue:
$36.71B
Net Income/Loss:
$7.71B
P/E Ratio:
25.74
EPS:
14.2284
Net Cash Flow:
$9.96B
1W Performance:
+7.01%
1M Performance:
+11.77%
6M Performance:
+21.28%
1Y Performance:
+26.70%
1-Day Range:
$342.38
$368.75
1-Week Range:
$338.07
$368.75
52-Week Range:
$261.43
$368.75
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
366.20 | 182.32B | 36.71B | 7.71B | 9.96B | 14.23 |
|
LLY
Lilly Eli Co
|
1,107.12 | 898.12B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
234.47 | 561.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
217.11 | 398.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
118.33 | 287.52B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
NVS
Novartis Ag Adr
|
152.91 | 287.55B | 54.45B | 14.42B | 17.15B | 7.333 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Why is Amgen stock falling premarket? - MSN
Why Is Amgen Stock Falling Premarket? - Stocktwits
BI Asset Management Fondsmaeglerselskab A S Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen Hits 52-Week Highs: Buy Signal? - Investing.com
Amgen Inc. $AMGN Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Jones Financial Companies Lllp Has $10.89 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Bank of America Maintains Underperform on Amgen Inc (AMGN) Feb 2026 - Meyka
Is It Time To Reassess Amgen (AMGN) After Strong Recent Share Price Gains - Yahoo Finance
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open - TechStock²
Amgen Earnings Call: Broad Growth Amid Manageable Risks - TipRanks
Amgen (AMGN) Surges on Q4 Earnings Beat, Leading Dow Gains - GuruFocus
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal? - Finviz
Amgen Seen Driving Long-Term Growth on R&D Pipeline, Oppenheimer Says - marketscreener.com
Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus - TechStock²
Amgen climbs 8% after upbeat earnings report - breakingthenews.net
Deep Dive Into Amgen Stock: Analyst Perspectives (14 Ratings) - Benzinga
BofA Securities reiterates Underperform rating on Amgen stock at $304 - Investing.com
Amgen Inc (AMGN) Stock Price Up 7.36% on Feb 4 - GuruFocus
Cantor Fitzgerald Raises Price Target for Amgen (AMGN) to $350 | - GuruFocus
Amgen thumbs-down on FDA’s ask, Tavneos sales continue - BioWorld MedTech
Cantor Fitzgerald Increases Amgen (NASDAQ:AMGN) Price Target to $350.00 - MarketBeat
Amgen’s FORTITUDE-301 Cancer Trial Completion: What Investors Should Watch in Bemarituzumab’s Next Act - TipRanks
Amgen Inc. (NASDAQ:AMGN) Q4 2025 earnings call transcript - MSN
Cantor Fitzgerald raises Amgen stock price target to $350 on strong earnings - Investing.com
Why Amgen Stock Is Paying Off Big For Long-Term Investors - Forbes
Leerink Partners Adjusts Price Target on Amgen to $355 From $305, Maintains Market Perform Rating - marketscreener.com
AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus - TradingView
Amgen (NASDAQ:AMGN) Sets New 1-Year High Following Strong Earnings - MarketBeat
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive
Amgen's Diversified Portfolio and Growing Cardiovascular Focus Support a Wide Moat - Morningstar
Amgen stock reaches all-time high of $353.74 By Investing.com - Investing.com Canada
Amgen stock reaches all-time high of $353.74 - Investing.com
Morgan Stanley Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
The Goldman Sachs Group Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Amgen stock price target raised to $360 from $335 at RBC Capital - Investing.com
Leerink Partners Raises Amgen (AMGN) Price Target to $355 | AMGN Stock News - GuruFocus
Street View: Amgen banks on pipeline depth and long term weight-loss play - TradingView
Amgen (NASDAQ:AMGN) Price Target Raised to $355.00 - MarketBeat
Amgen Fell 4% Last Week. Here’s Where the Stock Could Head in 2026 - TIKR.com
Amgen Inc. (NASDAQ:AMGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge (AMGN) - Seeking Alpha
Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma
Goldman Sachs Adjusts Price Target on Amgen to $415 From $403, Maintains Buy Rating - marketscreener.com
Amgen stock price target raised to $420 from $389 at TD Cowen - Investing.com
AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook - Finviz
Amgen posts double-digit revenue and EPS growth for 2025 - The Pharma Letter
Amgen Drops Eczema Drug Pact As Investors Weigh R&D Focus And Valuation - simplywall.st
Amgen (NASDAQ:AMGN) Stock Unloaded Rep. David Taylor - MarketBeat
Rep. David Taylor Buys Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
6.18%
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):